logo
Plus   Neg
Share
Email

6 Top Gainers In Pharma Sector (PRPO, ATEC, SYBX...)

pharmaup-april30-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. Precipio Inc. (PRPO)

Precipio is a cancer diagnostics company.

Gained 20.04% to close Tuesday's (Apr.30) trading at $6.05.

News: The Company has signed a services contract with a health care management group serving several major hospitals based in Cairo, Egypt. The contract is expected to generate over $1.5 million in revenues annually for Precipio.

Recent event:

In order to regain compliance with the Nasdaq minimum bid price requirement of $1.00, Precipio implemented a 1-for-15 reverse stock split on April 26, 2019, and its shares began trading on a split-adjusted basis at the open of business on Monday, April 29, 2019.

2. Quorum Health Corporation (QHC)

Quorum Health is a provider of hospital and outpatient healthcare services in its markets across the United States.

Gained 19.88% to close Tuesday's trading at $2.05.

News: No news

Recent events:

-- On April 15, 2019, the Company completed the sale of a 146-bed Scenic Mountain Medical Center in Big Springs, Texas. The total proceeds from the sale were approximately $22 million.
-- On March 12, 2019, the Company reported financial and operating results for the fourth quarter and year ended December 31, 2018.

Full-year net loss attributable to Quorum Health in 2018 was $200.2 million, or $6.91 per share on revenue of $1.88 billion. This compared with a net loss attributable to the Company of $114.2 million or $4.06 per share and revenue of $2.07 billion in 2017.

Looking ahead to 2019, the Company expects revenue to range between $1.83 billion to $1.88 billion.

Near-term Catalyst:

The Company is slated to report its first quarter 2019 financial results in the second week of May.

3. Alphatec Holdings Inc. (ATEC)

Alphatec is a medical device company that designs, develops and markets spinal fusion technology products and solutions for the treatment of spinal disorders.

Gained 16.44% to close Tuesday's trading at $4.25.

News: No news

Recent event:

On March 7, 2019, the Company reported fourth quarter and fiscal year 2018 financial results.

The net loss for the fourth quarter of 2018 was $10.63 million or $0.25 per share compared to a net profit of $9.05 million or $0.53 per share in the year-ago quarter. Total revenue in the fourth quarter of 2018 declined to $25.34 million from $26.28 million in the year-ago quarter.

Near-term Catalyst:

The Company is slated to release first quarter 2019 financial results on Thursday, May 9, 2019, after the market closes.

4. G1 Therapeutics Inc. (GTHX)

G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.

Gained 15.30% to close Tuesday's trading at $21.40.

News: The Company received positive feedback from its end-of-phase II meeting with the FDA and discussions with European regulatory authorities related to Trilaciclib in small-cell lung cancer.

Trilaciclib is being evaluated in four phase II clinical trials - three studies in patients with small-cell lung cancer (SCLC), and one study in patients with triple-negative breast cancer.

5. Avadel Pharmaceuticals plc (AVDL)

Gained 11.61% to close Tuesday's trading at $1.25.

Avadel is a branded specialty pharmaceutical company, generating revenue primarily from the sale of pharmaceutical products, previously sold in the U.S. without FDA approval ("Unapproved Marketed Products" or "UMDs").

Pipeline:

The lead drug candidate FT218 for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy is under phase III testing. The study is expected to be completed in September 2019 (Source: ClinicalTrials.gov).

Near-term Catalyst:

The Company is expected to report its financial results for the first quarter ended March 31, 2019, on May 8, 2019.

6. Synlogic Inc. (SYBX)

Synlogic is a clinical-stage biopharmaceutical company developing synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States.

Gained 10.85% to close Tuesday's trading at $8.58.

News: The Company presented data demonstrating its development of a robust and reproducible process to generate a solid oral formulation of its Synthetic Bioticmedicine, SYNB1618, at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy.

SYNB1618 is under a phase 1/2a study in patients with phenylketonuria.

Near-term Catalysts:

-- Topline data from phase 1b/2a clinical trial of SYNB1020 in patients with cirrhosis and elevated ammonia are expected in mid-2019.
-- Topline data from phase 1/2a study of SYNB1618 in patients with Phenylketonuria is expected in mid-2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT